STOCK TITAN

Adaptive Biotechnologies to Present at the BofA Securities 2022 Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Adaptive Biotechnologies, a biotechnology company listed on Nasdaq under the symbol ADPT, announced its participation in the BofA Securities 2022 Healthcare Conference in Las Vegas. Management will host a fireside chat on May 11 at 8:40 a.m. PT. Interested individuals can access the live and archived webcast via the company's website. Adaptive focuses on leveraging the adaptive immune system to develop clinical products for disease diagnosis and treatment, with a robust pipeline targeting cancer, autoimmune, and infectious diseases.

Positive
  • None.
Negative
  • None.

SEATTLE, May 02, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming BofA Securities 2022 Healthcare Conference in Las Vegas, Nevada.

Adaptive Biotechnologies’ management is scheduled to participate in a fireside chat Wednesday, May 11th at 8:40 a.m. Pacific Time / 11:40 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in our Immune Medicine and Minimal Residual Disease (MRD) businesses. We have three commercial products and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. For more information, please visit adaptivebiotech.com and follow us on www.twitter.com/adaptivebiotech.

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
Carrie Mendivil, Gilmartin Group
investors@adaptivebiotech.com 

ADAPTIVE MEDIA
Laura Cooper, Senior Director, Corporate Communications
206-693-2042
lcooper@adaptivebiotech.com 


FAQ

When is Adaptive Biotechnologies participating in the BofA Securities Healthcare Conference?

Adaptive Biotechnologies will participate on May 11, 2022, at 8:40 a.m. Pacific Time.

How can I access the webcast of the Adaptive Biotechnologies presentation?

You can access the live and archived webcast on the 'Investors' section of Adaptive Biotechnologies' website.

What is the stock symbol for Adaptive Biotechnologies?

The stock symbol for Adaptive Biotechnologies is ADPT.

What is the focus of Adaptive Biotechnologies?

Adaptive Biotechnologies focuses on translating the genetics of the adaptive immune system into clinical products for diagnosing and treating diseases.

What types of diseases does Adaptive Biotechnologies target?

Adaptive Biotechnologies targets diseases such as cancer, autoimmune conditions, and infectious diseases.

Adaptive Biotechnologies Corporation

NASDAQ:ADPT

ADPT Rankings

ADPT Latest News

ADPT Stock Data

785.29M
147.47M
1.93%
98.62%
6.43%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SEATTLE